93 results about "Heparanase" patented technology

Qualitative and quantitative methods of testing an agent for its potential at inhibiting glycosidase catalytic activity, the methods including the steps of interacting a glycosidase enzyme with a glycosidase substrate in a presence of the agent and qualitatively or quantitatively evaluating an effect of the agent on the catalytic activity of the glycosidase enzyme toward the glycosidase substrate. Preferably the glycosidase enzyme is a heparanase enzyme and the glycosidase substrate is, respectively, a heparanase substrate.

The invention relates to a method for determining endoglycosidase enzyme activity, and in particular of the heparanase type, in a sample, and also to a method for detecting a compound capable of modulating the activity of an endoglycosidase, and in particular of an endoglycosidase having activity of the heparanase type, by measuring a signal resulting from a close proximity transfer between two compounds attached to a substrate for the enzyme.

A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.

Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives have antiangiogenic and heparanase-inhibiting activity and are devoid of anticoagulant activity.

Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis.

A method of preparing low molecular weight heparin or low molecular weight heparan sulfate, the method is effected by digesting unfractionated or partially fractionated heparin or heparan sulfate having a given preponderant molecular mass with heparanase, thereby obtaining beparin or heparan sulfate of a lower preponderant molecular mass. A product obtained by implementing the method and a pharmaceutical composition including the latter are also described.

Methods of improving embryo implantation are disclosed and comprise contacting a receptive uterus and / or an embryo with an effective amount of heparanase and implanting the embryo in the receptive uterus.

A transgenic non-human animal expressing heparanase from a transgene, methods for its preparation, compositions-of-matter derived therefrom and uses thereof.

The invention discloses a heparanase III fusion protein and a coding gene and an expression method thereof. The fusion protein of the invention (named as MBP-HepC) is a protein in a) or b): a) a protein consisting of amino acid sequences shown by the 1-1028th site of a sequence 2 in a sequence table; and b) a protein derived from a), provided with heparanase III activity and obtained by substituting and / or deleting and / or adding one or more amino acids in an amino acid sequence of the sequence 2 in the sequence table. The coding gene of the protein is also within the protection range of the invention. By introducing the gene into protein heparanase expressed in recombinant escherichia coli, the enzymatic activity can reach 1,776.3 IU per liter of fermentation liquid, the expression amount can reach 240 mg per liter of fermentation liquid, and the specific enzymatic activity can reach 7.39 IU / mg. The invention also can realize further purification of the fusion protein through affinity separation.

Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly formula (I) compounds where the U, R and R1 groups have the meanings indicated in the description. Said glycosaminoglycan derivatives are endowed with antiangiogenic and heparanase-inhibiting activity ans are devoid of anticoagulant activity.

A method for reducing cytotoxicity of eosinophil derived toxins comprising administering to a subject an effective amount of heparin, heparan sulfate, a potent heparanase inhibitor or a polypeptide which has sequence as follows: BZBXBX, XBBBXXBX, XBBXBX, BBXXBBBXXBB, BXBBXB, XBBBXXBBBXXBBX, or TXXBXXTBXXXTBB, wherein X represents any amino acid, Z represents an aromatic amino acid, and B represents a basic amino acid and T represents a turn.

A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.

Methods and compositions for inducing and / or accelerating wound healing and / or angiogenesis via the catalytic activity of heparanase are disclosed.

The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof.

The invention relates to application of ginsenoside in the field of pharmacy, in particular to application of ginsenoside used as a heparanase inhibitor in preparation of tumor therapeutic drug. Through tests, the compound has high safety and good inhibition effect on heparanase under the test dosage, and can be used for treating tumors.

Wrinkles are improved by applying an oral preparation, injection preparation or external skin preparation having a substance that controls heparanase as an active ingredient thereof.

The invention belongs to the technical field of the preparation of livestock molecular markers and particularly relates to preparation and application of pig molecular markers. The preparation method comprises the steps: cloning from a human source HPSE (Heparanase) gene to obtain a gene fragment applied as a molecular marker relevant to pig immune characters, wherein the nucleotide sequence of the gene fragment is disclosed as SEQ ID No:2, and A80-G80 base substitution exists in the 80bp position of the SEQ ID No:2 to lead to the polymorphism of Alu I-RFLP (Restricted Fragment Length Polymorphisms). The invention also discloses a method for preparing molecular markers relevant to pig immune characters and application of the prepared molecular markers to the detection of the polymorphism of the pig immune characters. The invention provides a new marker for the assisted selection of pig markers.

Methods and compositions for inducing and / or accelerating wound healing and / or angiogenesis via the catalytic activity of heparanase are disclosed.

Embodiments of the present invention concern methods related to treating, prognosticating and / or diagnosing at least brain metastatic breast cancer. Embodiments of the methods include characterizing circulating tumor cells for the presence or absence of EpCAM and, upon identification of EpCAM negative cells and identification of the status of other markers (such as heparanase and / or Notch1, for example), treating the individual based on the determination of the characterization.

The present invention relates to inhibition of heparinoids anti-coagulation activity by a non-active form of a eukaryotic endoglycosidase or any fragment or peptide thereof comprising at least one heparin-binding domain. More particularly, the invention provides compositions and methods for the inhibition of heparinoids anti-coagulation activity and for the treatment of coagulation related pathologic clinical conditions, using a non-active form of mammalian heparanase or peptides thereof comprising at least one heparin-binding domain.

The invention relates to the technical field of in vitro diagnostic reagents, and particularly relates to a lyophilized heparanase preparation, a heparanase cup as well as a preparation method and application of the lyophilized heparanase preparation and the heparanase cup. A redissolved enzyme activity yield of the lyophilized heparanase preparation provided by the invention is at least 75 percent. The heparanase cup provided by the invention comprises a cup body and the lyophilized heparanase preparation, wherein an accommodating space is defined in the cup body; the lyophilized heparanase preparation is arranged in the accommodating space. The invention also provides a method for preparing the lyophilized heparanase preparation. The method comprises the following steps: sequentially performing pre-freezing treatment, sublimation treatment and drying treatment on aqueous solutions prepared from heparinase, a protective agent, buffer salt and a preservative in a predetermined proportion so as to obtain the lyophilized heparanase preparation. The lyophilized heparanase preparation and the heparanase cup are used in a detection process of blood samples, and the detection sensitivityis high; moreover, the activity and the stability of the heparinase in a lyophilization process can be obviously improved.

The invention provides a novel gene therapy drug construct for treating a type 3A mucopolysaccharidosis. The novel gene therapy drug construct can efficiently express recombinant human heparanase-N-sulfatase (SGSH) for preparation of a gene therapy drug product mediated by an adeno-associated virus vector.